# Sorafenib In Egyptian Patients With Hepatocellular Carcinoma.

> **NCT06030895** · NA · COMPLETED · sponsor: **Damanhour University** · enrollment: 100 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Sorafenib Tablets

## Key facts

- **NCT ID:** NCT06030895
- **Lead sponsor:** Damanhour University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-12
- **Primary completion:** 2024-02-21
- **Final completion:** 2024-03-01
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2024-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06030895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06030895, "Sorafenib In Egyptian Patients With Hepatocellular Carcinoma.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06030895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*